SPC-14 / Silo Pharma, Columbia University - LARVOL DELTA

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug (GlobeNewswire) - "Silo Pharma, Inc...today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University....The patent, titled 'Compositions and Methods for the Treatment of Alzheimer’s Disease and Other Neurogenerative Disease,' covers SPC-14’s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD."

Patent • Alzheimer's Disease

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic (GlobeNewswire) - "Silo Pharma, Inc...today announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer’s drug SPC-14. Silo intends to utilize the FDA’s streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs."

Licensing / partnership • Alzheimer's Disease • CNS Disorders

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study (GlobeNewswire) - "Silo Pharma, Inc...announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals. Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety). The mice were treated twice daily with the SPC-14 therapeutic."

Preclinical • Alzheimer's Disease • CNS Disorders

Exploring the Fatty Acid Binding Pocket in the SARS-CoV-2 Spike Protein - Confirmed and Potential Ligands. (PubMed, J Chem Inf Model) - "The next identified ligand, lifitegrast, was also experimentally confirmed as a ligand with antiviral activity, suggesting the potential for diverse chemical scaffolds to bind this site. Finally, SPC-14 was also confirmed as a ligand, although no inhibition assays were performed...Compounds able to bind this site with high affinity have the potential to stabilize the inactive conformation of the SARS-CoV-2 spike protein and therefore reduce the virus's ability to infect new cells. Since this pocket is conserved in highly pathogenic human coronaviruses, including MERS-CoV and SARS-CoV, this effect could be exploited for the development of new antiviral agents, with broad-spectrum anticoronavirus activity."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

In Silico Discovery of Small Molecule Modulators Targeting the Achilles' Heel of SARS-CoV-2 Spike Protein. (PubMed, ACS Cent Sci) - "Furthermore, the cryo-EM structure of the compound SPC-14 bound spike revealed that SPC-14 could shift the conformational equilibrium of the spike protein toward the closed conformation, which is human ACE2 (hACE2) inaccessible. Our identified small molecule modulators targeting the conserved FFA-binding pocket could serve as the starting point for the future development of broad-spectrum COVID-19 intervention treatments."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study (GlobeNewswire) - “Silo Pharma, Inc…announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD), as demonstrated in a mouse model. The research was conducted as part of a sponsored research agreement with Columbia University in New York. SPC-14, a novel drug that combines an FDA-approved therapeutic with ketamine, is in development for the treatment of dementia related to Alzheimer's disease. Initial data from its SPC-14 research studies shows that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no negative weight effects on the subjects.”

Preclinical • Alzheimer's Disease • CNS Disorders

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics (GlobeNewswire) - “Silo Pharma, Inc…announced it has entered into an agreement with Columbia University pursuant to which Silo has been granted an extension for its option to license certain assets currently under development, including Alzheimer’s disease and Stress Induced Anxiety. ‘The first steps of our research with Columbia have been positive and we’re happy to extend this research and option pact to continue the progress of SPC-14 as an Alzheimer's therapeutic and SPC-15 for Stress Induced Anxiety disorders’…On-going research studies are currently being conducted by Silo and we look forward to sharing these results as data becomes available.”

Licensing / partnership • Alzheimer's Disease • CNS Disorders